Literature DB >> 9428430

Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment.

J L Guate1, S Escaf, C L Menendez, M del Valle, J A Vega.   

Abstract

The present study was undertaken to analyze the changes in neuroendocrine cells of the human prostate induced by neoplasms and the effect of hormonal treatment. Samples of human prostate (n = 47) were obtained during surgery or removal of organs for transplantation. The cases analyzed represent normal prostates (n = 4); benign prostatic hyperplasias (n = 10; prostatic carcinomas with Gleason scores of 2-4 (n = 5), 5-7 (n = 10), and 8-10 (n = 3), and prostatic carcinomas treated with hormonal therapy (n = 15). Immunohistochemistry for chromogranin A was performed, and the density of neuroendocrine cells as well as the intensity of the immunostaining within their cytoplasms were evaluated using image analysis. Neuroendocrine cells showing chromogranin A immunoreactivity were identified in all cases studied. They were localized scattered in the acini, and no differences in their morphology were observed among groups. Interestingly, chromogranin A immunoreactivity was also present in typical epithelial cells of prostatic cancer with Gleason scores ranging from 8 to 10. The density of chromogranin A immunoreactive cells was higher in neoplastic tissue with respect to the normal prostate, reaching maximal values in prostatic carcinomas with Gleason scores of 8-10 which were hormonally treated. Regarding the intensity of immunostaining in the prostatic carcinomas with Gleason scores of 8-10 only, a significant increase in relation to the other groups was found. The present results demonstrate that the neuroendocrine cells have similar morphological features and distribution in normal prostate, benign prostatic hyperplasia, and prostatic carcinoma. Their density in prostatic cancer increases following hormonal therapy and varies in relation to the tumoral degree or histological evaluation, suggesting a role of neuroendocrine cells in human prostatic cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9428430     DOI: 10.1159/000283051

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

1.  Voltage-dependent ion channel currents in putative neuroendocrine cells dissociated from the ventral prostate of rat.

Authors:  Jun Hee Kim; Sun Young Shin; Sang Soon Yun; Tae Jin Kim; Seung-June Oh; Kwang Myung Kim; Young-Shin Chung; Eun-Kyoung Hong; Dae-Yong Uhm; Sung Joon Kim
Journal:  Pflugers Arch       Date:  2003-02-21       Impact factor: 3.657

2.  Dietary tomato and lycopene impact androgen signaling- and carcinogenesis-related gene expression during early TRAMP prostate carcinogenesis.

Authors:  Lei Wan; Hsueh-Li Tan; Jennifer M Thomas-Ahner; Dennis K Pearl; John W Erdman; Nancy E Moran; Steven K Clinton
Journal:  Cancer Prev Res (Phila)       Date:  2014-10-14

Review 3.  Somatostatin receptors and their interest in diagnostic pathology.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Mauro Papotti
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

4.  A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.

Authors:  Lawrence D True; Kent Buhler; Janna Quinn; Emily Williams; Peter S Nelson; Nigel Clegg; Jill A Macoska; Thomas Norwood; Alvin Liu; William Ellis; Paul Lange; Robert Vessella
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

5.  EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.

Authors:  Rosa M Martín-Orozco; Carmén Almaraz-Pro; F Javier Rodríguez-Ubreva; M Alicia Cortés; Santiago Ropero; Ramón Colomer; Pilar López-Ruiz; Begoña Colás
Journal:  Neoplasia       Date:  2007-08       Impact factor: 5.715

6.  Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells.

Authors:  Michael E Wright; Jimmy Eng; James Sherman; David M Hockenbery; Peter S Nelson; Timothy Galitski; Ruedi Aebersold
Journal:  Genome Biol       Date:  2003-12-23       Impact factor: 13.583

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.